Research and development Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients
Read morePress releases
- GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma
- First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
- European Medicines Agency accepts submission of GSK’s Marketing Authorisation Application for Zejula (niraparib) in first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
Tweets from GSK
-
GSK @GSK
“We need to find a new regimen that’s shorter, faster-acting, safer, and one that’s really effective in all forms of TB” - Pauline Williams, SVP, Head of Global health R&D, speaks to Devex about the need for partnerships to tackle TB. twitter.com/devex/status/1…
about 11 hours ago
-
GSK @GSK
According to @WHO #TB claims 4,000 lives every single day. The need for new TB treatment regimens is urgent, but we can’t tackle it alone. That’s why we’re proud to join #PANTB collaborating with other pharma companies and @gatesfoundation to tackle TB. gsk.to/3adlxho
about 12 hours ago -
GSK @GSK
We’re contributing to the global response to #COVID19 and supporting the development of candidate vaccines by providing our adjuvant technology to China-based Clover Biopharmaceuticals. Learn more: gsk.to/390Wv4k #coronavirus
about 3 days ago
